ciprofloxacin has been researched along with avibactam in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, S; Ammeter, D; Brizuela, M; Idowu, T; Jackson, G; Schweizer, F | 1 |
| Kumar, M; Kumar, R; Kumar, S; Maurya, SK; Nandanwar, H; Pathania, V | 1 |
| Gales, AC; Sahm, DF; Stone, G; Utt, E; Wise, MG | 1 |
3 other study(ies) available for ciprofloxacin and avibactam
| Article | Year |
|---|---|
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Structure-Activity Relationship; Tobramycin | 2020 |
Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-β-lactam-β-lactamase inhibitors.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Combinations; Escherichia coli; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Staphylococcus aureus | 2023 |
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Combinations; Escherichia coli; Incidence; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2023 |